Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-28T23:58:23.208Z Has data issue: false hasContentIssue false
  • English
  • Français

Neurobiological susbtrates in deficit and non deficit schizophrenia

Published online by Cambridge University Press:  16 April 2020

C. Arango
C. Arango*
Affiliation:
Department of Psychiatry, Hospital Gral. Univ. Gregorio Marañón, Madrid, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The deficit syndrome defines a subgroup of schizophrenia patients with prominent and enduring primary negative symptoms (1). Behavioral, structural, and functional neuroimaging studies have implicated mainly the dorsolateral prefrontal - thalamocortical circuit. Deficit syndrome patients seem to have larger ventricles in MRI studies (2). Neurological soft signs suggest parietal involvement with greater sensory integration impairment in deficit syndrome patients (3). On the contrary, some biological markers such as P50 gating have not shown any difference between deficit and non-deficit schizophrenia (4). Finally, no pharmacological treatment has so far proven effective for the treatment of primary enduring negative symptoms (5). In conclusion, deficit pathology in schizophrenia seems to involve the prefrontal and parietal lobes and have different neurobiological substrates than positive symptoms.

Type
S16-02
Information
European Psychiatry , Volume 26 , Issue S2: Abstracts of the 19th European Congress of Psychiatry , March 2011 , pp. 2069
Copyright
Copyright © European Psychiatric Association 2011

References

Carpenter, W.T. Jr.Heinrichs, D.W.Wagman, A.M.Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 14551988 578583Google ScholarPubMed
Arango, C.McMahon, R.P.Lefkowitz, D.M.Pearlson, G.Kirkpatrick, B.Buchanan, R.W.Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. Psychiatry Res 16222008 9110010.1016/j.pscychresns.2007.06.002CrossRefGoogle ScholarPubMed
Arango, C.Kirkpatrick, B.Buchanan, R.W.Neurological signs and the heterogeneity of schizophrenia. Am J Psychiatry 15742000 56056510.1176/appi.ajp.157.4.560CrossRefGoogle ScholarPubMed
Santos, J.L.Sánchez-Morla, E.M.Aparicio, A.García-Jiménez, M.A.Villanueva, C.Martínez-Vizcaíno, V.Arango, C.P50 gating in deficit and nondeficit schizophrenia. Schizophr Res 1191–32010 18319010.1016/j.schres.2010.01.010CrossRefGoogle ScholarPubMed
Arango, C.Buchanan, R.W.Kirkpatrick, B.Carpenter, W.T.The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry 1912004 212610.1016/j.eurpsy.2003.10.004CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.